HEADER TRANSFERASE 04-FEB-04 1S9G TITLE CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) IN COMPLEX WITH TITLE 2 JANSSEN-R120394. COMPND MOL_ID: 1; COMPND 2 MOLECULE: POL POLYPROTEIN [CONTAINS: REVERSE TRANSCRIPTASE]; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: P66 SUBUNIT; COMPND 5 SYNONYM: HIV-1 RT; COMPND 6 EC: 2.7.7.49; COMPND 7 ENGINEERED: YES; COMPND 8 MUTATION: YES; COMPND 9 MOL_ID: 2; COMPND 10 MOLECULE: POL POLYPROTEIN [CONTAINS: REVERSE TRANSCRIPTASE]; COMPND 11 CHAIN: B; COMPND 12 FRAGMENT: P51 SUBUNIT; COMPND 13 SYNONYM: HIV-1 RT; COMPND 14 EC: 2.7.7.49; COMPND 15 ENGINEERED: YES; COMPND 16 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 GENE: POL; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BH10 ISOLATE; SOURCE 8 OTHER_DETAILS: HIV-1 CLONE 12; SOURCE 9 MOL_ID: 2; SOURCE 10 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 11 ORGANISM_TAXID: 11676; SOURCE 12 GENE: POL; SOURCE 13 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 14 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 15 EXPRESSION_SYSTEM_STRAIN: BH10 ISOLATE; SOURCE 16 OTHER_DETAILS: HIV-1 CLONE 12 KEYWDS AIDS, HIV, DRUG DESIGN, REVERSE TRANSCRIPTASE, RT, PROTEIN-INHIBITOR KEYWDS 2 COMPLEX, R120393, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR K.DAS,A.D.CLARK JR.,D.W.LUDOVICI,M.J.KUKLA,B.DECORTE,P.J.LEWI, AUTHOR 2 S.H.HUGHES,P.A.JANSSEN,E.ARNOLD REVDAT 6 14-FEB-24 1S9G 1 REMARK REVDAT 5 27-OCT-21 1S9G 1 REMARK SEQADV SHEET REVDAT 4 31-JAN-18 1S9G 1 JRNL REMARK REVDAT 3 13-OCT-10 1S9G 1 REMARK REVDAT 2 24-FEB-09 1S9G 1 VERSN REVDAT 1 11-MAY-04 1S9G 0 JRNL AUTH K.DAS,A.D.CLARK,P.J.LEWI,J.HEERES,M.R.DE JONGE,L.M.KOYMANS, JRNL AUTH 2 H.M.VINKERS,F.DAEYAERT,D.W.LUDOVICI,M.J.KUKLA,B.DE CORTE, JRNL AUTH 3 R.W.KAVASH,C.Y.HO,H.YE,M.A.LICHTENSTEIN,K.ANDRIES,R.PAUWELS, JRNL AUTH 4 P.L.BOYER,P.CLARK,S.H.HUGHES,P.A.JANSSEN,E.ARNOLD JRNL TITL ROLES OF CONFORMATIONAL AND POSITIONAL ADAPTABILITY IN JRNL TITL 2 STRUCTURE-BASED DESIGN OF TMC125-R165335 (ETRAVIRINE) AND JRNL TITL 3 RELATED NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS THAT JRNL TITL 4 ARE HIGHLY POTENT AND EFFECTIVE AGAINST WILD-TYPE AND JRNL TITL 5 DRUG-RESISTANT HIV-1 VARIANTS. JRNL REF J.MED.CHEM. V. 47 2550 2004 JRNL REFN ISSN 0022-2623 JRNL PMID 15115397 JRNL DOI 10.1021/JM030558S REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH J.DING,K.DAS,H.MOEREELS,L.KOYMANS,K.ANDRIES,P.A.J.JANSSEN, REMARK 1 AUTH 2 S.H.HUGHES,E.ARNOLD REMARK 1 TITL STRUCTURE OF HIV-1 RT/TIBO R 86183 COMPLEX REVEALS REMARK 1 TITL 2 SIMILARITY IN THE BINDING OF DIVERSE NONNUCLEOSIDE REMARK 1 TITL 3 INHIBITORS REMARK 1 REF NAT.STRUCT.BIOL. V. 2 407 1995 REMARK 1 REFN ISSN 1072-8368 REMARK 1 REFERENCE 2 REMARK 1 AUTH J.DING,K.DAS,C.TANTILLO,W.ZHANG,A.D.CLARK JR.,S.JESSEN,X.LU, REMARK 1 AUTH 2 Y.HSIOU,A.JACOBO-MOLINA,K.ANDRIES,R.PAUWELS,H.MOEREELS, REMARK 1 AUTH 3 L.KOYMANS,P.A.J.JANSSEN,R.H.SMITH JR.,M.KROEGER KOEPKE, REMARK 1 AUTH 4 C.J.MICHEJDA,S.H.HUGHES,E.ARNOLD REMARK 1 TITL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN A COMPLEX WITH REMARK 1 TITL 2 THE NON-NUCLEOSIDE INHIBITOR ALPHA-APA R 95845 AT 2.8 A REMARK 1 TITL 3 RESOLUTION REMARK 1 REF STRUCTURE V. 3 365 1995 REMARK 1 REFN ISSN 0969-2126 REMARK 1 REFERENCE 3 REMARK 1 AUTH K.DAS,J.DING,Y.HSIOU,A.D.CLARK JR.,H.MOEREELS,L.KOYMANS, REMARK 1 AUTH 2 K.ANDRIES,R.PAUWELS,P.A.JANSSEN,P.L.BOYER,P.CLARK, REMARK 1 AUTH 3 R.H.SMITH JR.,M.B.KROEGER SMITH,C.J.MICHEJDA,S.H.HUGHES, REMARK 1 AUTH 4 E.ARNOLD REMARK 1 TITL CRYSTAL STRUCTURES OF 8-CL AND 9-CL TIBO COMPLEXED WITH REMARK 1 TITL 2 WILD-TYPE HIV-1 RT AND 8-CL TIBO COMPLEXED WITH THE REMARK 1 TITL 3 TYR181CYS HIV-1 RT DRUG-RESISTANT MUTANT REMARK 1 REF J.MOL.BIOL. V. 264 1085 1996 REMARK 1 REFN ISSN 0022-2836 REMARK 1 DOI 10.1006/JMBI.1996.0698 REMARK 1 REFERENCE 4 REMARK 1 AUTH J.DING,K.DAS,Y.HSIOU,S.G.SARAFIANOS,A.D.CLARK JR., REMARK 1 AUTH 2 A.JACOBO-MOLINA,C.TANTILLO,S.H.HUGHES,E.ARNOLD REMARK 1 TITL STRUCTURE AND FUNCTIONAL IMPLICATIONS OF THE POLYMERASE REMARK 1 TITL 2 ACTIVE SITE REGION IN A COMPLEX OF HIV-1 RT WITH A REMARK 1 TITL 3 DOUBLE-STRANDED DNA TEMPLATE-PRIMER AND AN ANTIBODY FAB REMARK 1 TITL 4 FRAGMENT AT 2.8 A RESOLUTION REMARK 1 REF J.MOL.BIOL. V. 284 1095 1998 REMARK 1 REFN ISSN 0022-2836 REMARK 1 DOI 10.1006/JMBI.1998.2208 REMARK 1 REFERENCE 5 REMARK 1 AUTH D.W.LUDOVICI,R.W.KAVASH,M.J.KUKLA,C.Y.HO,H.YE,B.L.DE CORTE, REMARK 1 AUTH 2 K.ANDRIES,M.DE BETHUNE,H.AZIJN,R.PAUWELS,H.E.MOEREELS, REMARK 1 AUTH 3 J.HEERES,L.M.KOYMANS,M.R.DE JONGE,K.J.VAN AKEN,F.F.DAEYAERT, REMARK 1 AUTH 4 P.J.LEWI,K.DAS,E.ARNOLD,P.A.JANSSEN REMARK 1 TITL EVOLUTION OF ANTI-HIV DRUG CANDIDATES PART 2: DIARYLTRIAZINE REMARK 1 TITL 2 (DATA) ANALOGUES REMARK 1 REF BIOORG.MED.CHEM.LETT. V. 11 2229 2001 REMARK 1 REFN ISSN 0960-894X REMARK 1 DOI 10.1016/S0960-894X(01)00411-5 REMARK 2 REMARK 2 RESOLUTION. 2.80 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.0 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.80 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 20.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 1.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 88.8 REMARK 3 NUMBER OF REFLECTIONS : 32836 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.242 REMARK 3 FREE R VALUE : 0.312 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 1664 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.008 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.80 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.97 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 74.70 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 4307 REMARK 3 BIN R VALUE (WORKING SET) : 0.3640 REMARK 3 BIN FREE R VALUE : 0.4320 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.40 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 244 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.028 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 7943 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 27 REMARK 3 SOLVENT ATOMS : 142 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.41 REMARK 3 ESD FROM SIGMAA (A) : 0.61 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.57 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.79 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.012 REMARK 3 BOND ANGLES (DEGREES) : 1.900 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : 1.280 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.24 REMARK 3 BSOL : 25.29 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : ION.PARAM REMARK 3 PARAMETER FILE 3 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 4 : 120.PAR REMARK 3 PARAMETER FILE 5 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : ION.TOP REMARK 3 TOPOLOGY FILE 3 : WATER.TOP REMARK 3 TOPOLOGY FILE 4 : 120.TOP REMARK 3 TOPOLOGY FILE 5 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1S9G COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 12-FEB-04. REMARK 100 THE DEPOSITION ID IS D_1000021534. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 6.80 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : CHESS REMARK 200 BEAMLINE : F1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.918 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 4 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 33445 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.800 REMARK 200 RESOLUTION RANGE LOW (A) : 40.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 90.3 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : 0.08300 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.80 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.90 REMARK 200 COMPLETENESS FOR SHELL (%) : 79.3 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.29000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: X-PLOR REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 63.28 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.38 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PEG 8000, AMMONIUM SULFATE, GLYCEROL, REMARK 280 TRIS, PH 6.80, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 280K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 111.80000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 34.30000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 111.80000 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 34.30000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5630 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 47690 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -32.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 544 REMARK 465 ASN A 545 REMARK 465 GLU A 546 REMARK 465 GLN A 547 REMARK 465 VAL A 548 REMARK 465 ASP A 549 REMARK 465 LYS A 550 REMARK 465 LEU A 551 REMARK 465 VAL A 552 REMARK 465 SER A 553 REMARK 465 ALA A 554 REMARK 465 GLY A 555 REMARK 465 ILE A 556 REMARK 465 ARG A 557 REMARK 465 LYS A 558 REMARK 465 ILE A 559 REMARK 465 LEU A 560 REMARK 465 PRO B 1 REMARK 465 ILE B 2 REMARK 465 GLN B 428 REMARK 465 LEU B 429 REMARK 465 GLU B 430 REMARK 480 REMARK 480 ZERO OCCUPANCY ATOM REMARK 480 THE FOLLOWING RESIDUES HAVE ATOMS MODELED WITH ZERO REMARK 480 OCCUPANCY. THE LOCATION AND PROPERTIES OF THESE ATOMS REMARK 480 MAY NOT BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 480 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 480 M RES C SSEQI ATOMS REMARK 480 LEU A 26 CG CD1 CD2 REMARK 480 PHE A 61 CG CD1 CD2 CE1 CE2 CZ REMARK 480 ILE A 63 CG1 CG2 CD1 REMARK 480 ARG A 72 CG CD NE CZ NH1 NH2 REMARK 480 GLU A 89 CG CD OE1 OE2 REMARK 480 ASP A 113 CG OD1 OD2 REMARK 480 GLU A 138 CG CD OE1 OE2 REMARK 480 THR A 139 OG1 CG2 REMARK 480 PRO A 140 CG CD REMARK 480 HIS A 221 CG ND1 CD2 CE1 NE2 REMARK 480 GLN A 222 CG CD OE1 NE2 REMARK 480 LYS A 223 CG CD CE NZ REMARK 480 GLN A 258 CG CD OE1 NE2 REMARK 480 GLN A 334 CG CD OE1 NE2 REMARK 480 GLN A 394 CG CD OE1 NE2 REMARK 480 GLN A 507 CG CD OE1 NE2 REMARK 480 LYS A 512 CG CD CE NZ REMARK 480 ASP B 67 CG OD1 OD2 REMARK 480 GLN B 222 CG CD OE1 NE2 REMARK 480 LYS B 223 CG CD CE NZ REMARK 480 GLU B 224 CG CD OE1 OE2 REMARK 480 PRO B 225 CG CD REMARK 480 LEU B 228 CG CD1 CD2 REMARK 480 TRP B 229 CG CD1 CD2 NE1 CE2 CE3 CZ2 REMARK 480 TRP B 229 CZ3 CH2 REMARK 480 GLN B 242 CG CD OE1 NE2 REMARK 480 ILE B 270 CG1 CG2 CD1 REMARK 480 LYS B 275 CG CD CE NZ REMARK 480 ILE B 293 CG1 CG2 CD1 REMARK 480 THR B 296 OG1 CG2 REMARK 480 GLU B 305 CG CD OE1 OE2 REMARK 480 ARG B 358 CG CD NE CZ NH1 NH2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 OH TYR A 232 NE2 GLN A 269 2.10 REMARK 500 O GLY B 231 N GLU B 233 2.12 REMARK 500 O LEU A 283 N GLY A 285 2.13 REMARK 500 O THR B 84 N ASP B 86 2.15 REMARK 500 OH TYR B 115 O MET B 184 2.17 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ASN A 54 N - CA - C ANGL. DEV. = -20.9 DEGREES REMARK 500 THR A 286 N - CA - C ANGL. DEV. = -20.4 DEGREES REMARK 500 GLY A 359 N - CA - C ANGL. DEV. = -19.1 DEGREES REMARK 500 PRO B 55 C - N - CA ANGL. DEV. = 10.4 DEGREES REMARK 500 GLU B 89 N - CA - C ANGL. DEV. = -17.4 DEGREES REMARK 500 PRO B 97 C - N - CA ANGL. DEV. = 11.0 DEGREES REMARK 500 MET B 230 N - CA - C ANGL. DEV. = 16.8 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 13 136.86 -37.09 REMARK 500 PRO A 14 -74.35 -9.47 REMARK 500 PRO A 52 156.31 -39.21 REMARK 500 PRO A 55 -13.53 -31.37 REMARK 500 SER A 68 58.54 35.32 REMARK 500 GLN A 91 19.23 46.81 REMARK 500 LYS A 104 -76.57 -83.33 REMARK 500 ASP A 110 73.72 -67.94 REMARK 500 ASP A 113 79.36 -48.01 REMARK 500 PRO A 119 -179.21 -64.21 REMARK 500 ASP A 121 123.02 -38.99 REMARK 500 SER A 134 42.16 -108.52 REMARK 500 ILE A 135 45.15 73.22 REMARK 500 ASN A 136 56.98 72.82 REMARK 500 ASN A 137 13.37 80.58 REMARK 500 PRO A 140 31.76 -69.41 REMARK 500 VAL A 148 -167.21 -116.62 REMARK 500 GLN A 151 17.39 -57.49 REMARK 500 ALA A 158 -71.86 -59.64 REMARK 500 SER A 162 -72.25 -56.40 REMARK 500 GLU A 169 -56.18 -8.57 REMARK 500 PRO A 170 -80.65 -53.85 REMARK 500 ASN A 175 79.71 -160.99 REMARK 500 MET A 184 -101.92 50.09 REMARK 500 ILE A 195 -24.88 -33.44 REMARK 500 THR A 216 89.31 -156.44 REMARK 500 LYS A 219 -101.00 -73.08 REMARK 500 LYS A 220 3.96 -41.67 REMARK 500 HIS A 221 44.44 82.78 REMARK 500 GLN A 222 -99.61 -23.31 REMARK 500 LYS A 223 129.41 -31.86 REMARK 500 MET A 230 32.24 39.72 REMARK 500 PRO A 243 138.30 -25.00 REMARK 500 PRO A 272 178.66 -40.37 REMARK 500 VAL A 276 1.88 -156.94 REMARK 500 LEU A 283 17.69 -68.62 REMARK 500 ARG A 284 43.04 -72.09 REMARK 500 LYS A 287 41.53 23.58 REMARK 500 ASP A 324 -177.06 -63.67 REMARK 500 GLN A 334 40.24 -88.30 REMARK 500 ARG A 358 115.23 -16.65 REMARK 500 ALA A 360 -3.34 -55.98 REMARK 500 THR A 362 159.30 179.88 REMARK 500 PRO A 392 44.07 -73.64 REMARK 500 LYS A 395 -48.77 -22.25 REMARK 500 PRO A 412 -176.87 -53.16 REMARK 500 THR A 419 89.78 -178.14 REMARK 500 PRO A 420 165.05 -44.78 REMARK 500 TRP A 426 3.49 -67.23 REMARK 500 TYR A 427 140.48 172.28 REMARK 500 REMARK 500 THIS ENTRY HAS 116 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: PLANAR GROUPS REMARK 500 REMARK 500 PLANAR GROUPS IN THE FOLLOWING RESIDUES HAVE A TOTAL REMARK 500 RMS DISTANCE OF ALL ATOMS FROM THE BEST-FIT PLANE REMARK 500 BY MORE THAN AN EXPECTED VALUE OF 6*RMSD, WITH AN REMARK 500 RMSD 0.02 ANGSTROMS, OR AT LEAST ONE ATOM HAS REMARK 500 AN RMSD GREATER THAN THIS VALUE REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI RMS TYPE REMARK 500 PHE B 130 0.09 SIDE CHAIN REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ABZ A 701 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1SV5 RELATED DB: PDB REMARK 900 1SV5 IS THE STRUCTURE OF K103N MUTANT HIV-1 REVERSE TRANSCRIPTASE REMARK 900 IN COMPLEX WITH JANSSEN-R165335 REMARK 900 RELATED ID: 1S9E RELATED DB: PDB REMARK 900 1S9E IS THE STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX REMARK 900 WITH JANSSEN-R129385 REMARK 900 RELATED ID: 1SUQ RELATED DB: PDB REMARK 900 ISUQ IS THE STRUCTURE OF K103N MUTANT HIV-1 REVERSE TRANSCRIPTASE REMARK 900 IN COMPLEX WITH JANSSEN-R165335 REMARK 900 RELATED ID: 1S6P RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE REMARK 900 TRANSCRIPTASE IN COMPLEX WITH JANSSEN-R100943 REMARK 900 RELATED ID: 1S6Q RELATED DB: PDB REMARK 900 1S6Q IS THE CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) REMARK 900 IN COMPLEX WITH JANSSEN-R147681 REMARK 900 RELATED ID: 1HNV RELATED DB: PDB REMARK 900 1HNV IS THE STRUCTURE OF HIV-1 RT/TIBO R 86183 COMPLEX REMARK 900 RELATED ID: 1HNI RELATED DB: PDB REMARK 900 1HNI IS THE STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN A COMPLEX REMARK 900 WITH THE NON-NUCLEOSIDE INHIBITOR ALPHA-APA R 95845 REMARK 900 RELATED ID: 1DLO RELATED DB: PDB REMARK 900 RELATED ID: 1TVR RELATED DB: PDB REMARK 900 RELATED ID: 2HMI RELATED DB: PDB REMARK 900 2HMI IS HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH A DOUBLE - REMARK 900 STRANDED DNA AND FAB28 DBREF 1S9G A 1 560 UNP P03366 POL_HV1B1 168 727 DBREF 1S9G B 1 430 UNP P03366 POL_HV1B1 168 597 SEQADV 1S9G SER A 280 UNP P03366 CYS 447 ENGINEERED MUTATION SEQADV 1S9G SER B 280 UNP P03366 CYS 447 ENGINEERED MUTATION SEQRES 1 A 560 PRO ILE SER PRO ILE GLU THR VAL PRO VAL LYS LEU LYS SEQRES 2 A 560 PRO GLY MET ASP GLY PRO LYS VAL LYS GLN TRP PRO LEU SEQRES 3 A 560 THR GLU GLU LYS ILE LYS ALA LEU VAL GLU ILE CYS THR SEQRES 4 A 560 GLU MET GLU LYS GLU GLY LYS ILE SER LYS ILE GLY PRO SEQRES 5 A 560 GLU ASN PRO TYR ASN THR PRO VAL PHE ALA ILE LYS LYS SEQRES 6 A 560 LYS ASP SER THR LYS TRP ARG LYS LEU VAL ASP PHE ARG SEQRES 7 A 560 GLU LEU ASN LYS ARG THR GLN ASP PHE TRP GLU VAL GLN SEQRES 8 A 560 LEU GLY ILE PRO HIS PRO ALA GLY LEU LYS LYS LYS LYS SEQRES 9 A 560 SER VAL THR VAL LEU ASP VAL GLY ASP ALA TYR PHE SER SEQRES 10 A 560 VAL PRO LEU ASP GLU ASP PHE ARG LYS TYR THR ALA PHE SEQRES 11 A 560 THR ILE PRO SER ILE ASN ASN GLU THR PRO GLY ILE ARG SEQRES 12 A 560 TYR GLN TYR ASN VAL LEU PRO GLN GLY TRP LYS GLY SER SEQRES 13 A 560 PRO ALA ILE PHE GLN SER SER MET THR LYS ILE LEU GLU SEQRES 14 A 560 PRO PHE LYS LYS GLN ASN PRO ASP ILE VAL ILE TYR GLN SEQRES 15 A 560 TYR MET ASP ASP LEU TYR VAL GLY SER ASP LEU GLU ILE SEQRES 16 A 560 GLY GLN HIS ARG THR LYS ILE GLU GLU LEU ARG GLN HIS SEQRES 17 A 560 LEU LEU ARG TRP GLY LEU THR THR PRO ASP LYS LYS HIS SEQRES 18 A 560 GLN LYS GLU PRO PRO PHE LEU TRP MET GLY TYR GLU LEU SEQRES 19 A 560 HIS PRO ASP LYS TRP THR VAL GLN PRO ILE VAL LEU PRO SEQRES 20 A 560 GLU LYS ASP SER TRP THR VAL ASN ASP ILE GLN LYS LEU SEQRES 21 A 560 VAL GLY LYS LEU ASN TRP ALA SER GLN ILE TYR PRO GLY SEQRES 22 A 560 ILE LYS VAL ARG GLN LEU SER LYS LEU LEU ARG GLY THR SEQRES 23 A 560 LYS ALA LEU THR GLU VAL ILE PRO LEU THR GLU GLU ALA SEQRES 24 A 560 GLU LEU GLU LEU ALA GLU ASN ARG GLU ILE LEU LYS GLU SEQRES 25 A 560 PRO VAL HIS GLY VAL TYR TYR ASP PRO SER LYS ASP LEU SEQRES 26 A 560 ILE ALA GLU ILE GLN LYS GLN GLY GLN GLY GLN TRP THR SEQRES 27 A 560 TYR GLN ILE TYR GLN GLU PRO PHE LYS ASN LEU LYS THR SEQRES 28 A 560 GLY LYS TYR ALA ARG MET ARG GLY ALA HIS THR ASN ASP SEQRES 29 A 560 VAL LYS GLN LEU THR GLU ALA VAL GLN LYS ILE THR THR SEQRES 30 A 560 GLU SER ILE VAL ILE TRP GLY LYS THR PRO LYS PHE LYS SEQRES 31 A 560 LEU PRO ILE GLN LYS GLU THR TRP GLU THR TRP TRP THR SEQRES 32 A 560 GLU TYR TRP GLN ALA THR TRP ILE PRO GLU TRP GLU PHE SEQRES 33 A 560 VAL ASN THR PRO PRO LEU VAL LYS LEU TRP TYR GLN LEU SEQRES 34 A 560 GLU LYS GLU PRO ILE VAL GLY ALA GLU THR PHE TYR VAL SEQRES 35 A 560 ASP GLY ALA ALA ASN ARG GLU THR LYS LEU GLY LYS ALA SEQRES 36 A 560 GLY TYR VAL THR ASN LYS GLY ARG GLN LYS VAL VAL PRO SEQRES 37 A 560 LEU THR ASN THR THR ASN GLN LYS THR GLU LEU GLN ALA SEQRES 38 A 560 ILE TYR LEU ALA LEU GLN ASP SER GLY LEU GLU VAL ASN SEQRES 39 A 560 ILE VAL THR ASP SER GLN TYR ALA LEU GLY ILE ILE GLN SEQRES 40 A 560 ALA GLN PRO ASP LYS SER GLU SER GLU LEU VAL ASN GLN SEQRES 41 A 560 ILE ILE GLU GLN LEU ILE LYS LYS GLU LYS VAL TYR LEU SEQRES 42 A 560 ALA TRP VAL PRO ALA HIS LYS GLY ILE GLY GLY ASN GLU SEQRES 43 A 560 GLN VAL ASP LYS LEU VAL SER ALA GLY ILE ARG LYS ILE SEQRES 44 A 560 LEU SEQRES 1 B 430 PRO ILE SER PRO ILE GLU THR VAL PRO VAL LYS LEU LYS SEQRES 2 B 430 PRO GLY MET ASP GLY PRO LYS VAL LYS GLN TRP PRO LEU SEQRES 3 B 430 THR GLU GLU LYS ILE LYS ALA LEU VAL GLU ILE CYS THR SEQRES 4 B 430 GLU MET GLU LYS GLU GLY LYS ILE SER LYS ILE GLY PRO SEQRES 5 B 430 GLU ASN PRO TYR ASN THR PRO VAL PHE ALA ILE LYS LYS SEQRES 6 B 430 LYS ASP SER THR LYS TRP ARG LYS LEU VAL ASP PHE ARG SEQRES 7 B 430 GLU LEU ASN LYS ARG THR GLN ASP PHE TRP GLU VAL GLN SEQRES 8 B 430 LEU GLY ILE PRO HIS PRO ALA GLY LEU LYS LYS LYS LYS SEQRES 9 B 430 SER VAL THR VAL LEU ASP VAL GLY ASP ALA TYR PHE SER SEQRES 10 B 430 VAL PRO LEU ASP GLU ASP PHE ARG LYS TYR THR ALA PHE SEQRES 11 B 430 THR ILE PRO SER ILE ASN ASN GLU THR PRO GLY ILE ARG SEQRES 12 B 430 TYR GLN TYR ASN VAL LEU PRO GLN GLY TRP LYS GLY SER SEQRES 13 B 430 PRO ALA ILE PHE GLN SER SER MET THR LYS ILE LEU GLU SEQRES 14 B 430 PRO PHE LYS LYS GLN ASN PRO ASP ILE VAL ILE TYR GLN SEQRES 15 B 430 TYR MET ASP ASP LEU TYR VAL GLY SER ASP LEU GLU ILE SEQRES 16 B 430 GLY GLN HIS ARG THR LYS ILE GLU GLU LEU ARG GLN HIS SEQRES 17 B 430 LEU LEU ARG TRP GLY LEU THR THR PRO ASP LYS LYS HIS SEQRES 18 B 430 GLN LYS GLU PRO PRO PHE LEU TRP MET GLY TYR GLU LEU SEQRES 19 B 430 HIS PRO ASP LYS TRP THR VAL GLN PRO ILE VAL LEU PRO SEQRES 20 B 430 GLU LYS ASP SER TRP THR VAL ASN ASP ILE GLN LYS LEU SEQRES 21 B 430 VAL GLY LYS LEU ASN TRP ALA SER GLN ILE TYR PRO GLY SEQRES 22 B 430 ILE LYS VAL ARG GLN LEU SER LYS LEU LEU ARG GLY THR SEQRES 23 B 430 LYS ALA LEU THR GLU VAL ILE PRO LEU THR GLU GLU ALA SEQRES 24 B 430 GLU LEU GLU LEU ALA GLU ASN ARG GLU ILE LEU LYS GLU SEQRES 25 B 430 PRO VAL HIS GLY VAL TYR TYR ASP PRO SER LYS ASP LEU SEQRES 26 B 430 ILE ALA GLU ILE GLN LYS GLN GLY GLN GLY GLN TRP THR SEQRES 27 B 430 TYR GLN ILE TYR GLN GLU PRO PHE LYS ASN LEU LYS THR SEQRES 28 B 430 GLY LYS TYR ALA ARG MET ARG GLY ALA HIS THR ASN ASP SEQRES 29 B 430 VAL LYS GLN LEU THR GLU ALA VAL GLN LYS ILE THR THR SEQRES 30 B 430 GLU SER ILE VAL ILE TRP GLY LYS THR PRO LYS PHE LYS SEQRES 31 B 430 LEU PRO ILE GLN LYS GLU THR TRP GLU THR TRP TRP THR SEQRES 32 B 430 GLU TYR TRP GLN ALA THR TRP ILE PRO GLU TRP GLU PHE SEQRES 33 B 430 VAL ASN THR PRO PRO LEU VAL LYS LEU TRP TYR GLN LEU SEQRES 34 B 430 GLU HET ABZ A 701 27 HETNAM ABZ 4-[4-AMINO-6-(5-CHLORO-1H-INDOL-4-YLMETHYL)-[1,3, HETNAM 2 ABZ 5]TRIAZIN-2-YLAMINO]-BENZONITRILE FORMUL 3 ABZ C19 H14 CL N7 FORMUL 4 HOH *142(H2 O) HELIX 1 1 THR A 27 GLU A 44 1 18 HELIX 2 2 PHE A 77 LYS A 82 1 6 HELIX 3 3 HIS A 96 LEU A 100 5 5 HELIX 4 4 GLY A 112 VAL A 118 5 7 HELIX 5 5 ASP A 121 ALA A 129 1 9 HELIX 6 6 GLY A 155 GLN A 174 1 20 HELIX 7 7 GLU A 194 ARG A 211 1 18 HELIX 8 8 THR A 253 GLN A 269 1 17 HELIX 9 9 VAL A 276 LEU A 283 1 8 HELIX 10 10 THR A 296 GLU A 312 1 17 HELIX 11 11 ASN A 363 GLY A 384 1 22 HELIX 12 12 GLN A 394 TYR A 405 1 12 HELIX 13 13 THR A 473 SER A 489 1 17 HELIX 14 14 SER A 499 ALA A 508 1 10 HELIX 15 15 SER A 515 LYS A 528 1 14 HELIX 16 16 THR B 27 GLU B 44 1 18 HELIX 17 17 PHE B 77 ARG B 83 1 7 HELIX 18 18 ASP B 86 GLN B 91 1 6 HELIX 19 19 GLY B 99 LYS B 103 5 5 HELIX 20 20 GLY B 112 VAL B 118 5 7 HELIX 21 21 ASP B 121 ALA B 129 1 9 HELIX 22 22 PHE B 124 ALA B 129 1 6 HELIX 23 23 SER B 134 GLU B 138 5 5 HELIX 24 24 GLY B 155 GLN B 174 1 20 HELIX 25 25 GLU B 194 GLY B 213 1 20 HELIX 26 26 THR B 253 SER B 268 1 16 HELIX 27 27 VAL B 276 LYS B 281 1 6 HELIX 28 28 THR B 296 LYS B 311 1 16 HELIX 29 29 ASN B 363 GLY B 384 1 22 HELIX 30 30 GLN B 394 TYR B 405 1 12 HELIX 31 31 PRO B 421 TYR B 427 1 7 SHEET 1 A 3 ILE A 47 ILE A 50 0 SHEET 2 A 3 ILE A 142 TYR A 146 -1 SHEET 3 A 3 THR A 128 ILE A 132 -1 SHEET 1 C 3 SER A 105 VAL A 111 0 SHEET 2 C 3 ASP A 186 SER A 191 -1 SHEET 3 C 3 ILE A 178 TYR A 183 -1 SHEET 1 D 2 PHE A 227 TRP A 229 0 SHEET 2 D 2 LYS A 238 THR A 240 -1 SHEET 1 E 4 LYS A 347 ALA A 355 0 SHEET 2 E 4 GLN A 336 TYR A 342 -1 SHEET 3 E 4 LEU A 325 GLN A 332 -1 SHEET 4 E 4 GLU A 413 THR A 419 1 SHEET 1 F 2 HIS A 361 THR A 362 0 SHEET 2 F 2 LYS A 512 SER A 513 -1 SHEET 1 G 4 LEU A 452 THR A 459 0 SHEET 2 G 4 GLU A 438 ASN A 447 -1 SHEET 3 G 4 GLU A 492 THR A 497 1 SHEET 4 G 4 LYS A 530 VAL A 536 1 SHEET 1 H 2 ILE B 142 TYR B 146 0 SHEET 2 H 2 ALA B 129 ILE B 132 -1 SHEET 1 J 3 ASP B 186 SER B 191 0 SHEET 2 J 3 SER B 105 ASP B 110 0 SHEET 3 J 3 GLU B 233 LEU B 234 -1 SHEET 1 K 4 ASN B 348 ALA B 355 0 SHEET 2 K 4 GLN B 336 TYR B 342 -1 SHEET 3 K 4 ILE B 326 LYS B 331 -1 SHEET 4 K 4 GLU B 413 VAL B 417 1 CISPEP 1 PRO A 225 PRO A 226 0 -0.19 CISPEP 2 PRO A 420 PRO A 421 0 -0.35 SITE 1 AC1 10 PRO A 95 LEU A 100 LYS A 101 VAL A 106 SITE 2 AC1 10 TYR A 181 TYR A 188 TRP A 229 LEU A 234 SITE 3 AC1 10 HOH A1001 GLU B 138 CRYST1 223.600 68.600 103.000 90.00 107.50 90.00 C 1 2 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.004472 0.000000 0.001410 0.00000 SCALE2 0.000000 0.014577 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010180 0.00000